Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia (BEST)
A Randomized Double-blind Trial of Aripiprazole and Risperidone in Schizophrenia: An Evaluation of Neuroimaging, Neuropsychological, and Pharmacogenomic Markers of Differential Treatment Response
Sponsor: Kettering Health Network
Terminated
Study terminated due to failure to meet sufficient enrollment for valid analysis
A PHASE4 clinical study on Schizophrenia, this trial is terminated or withdrawn. The trial is conducted by Kettering Health Network and has accumulated 9 data snapshots since 2005. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Aug 2020 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 4 earlier versions
-
Jan 2019 — Aug 2020 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2019 [monthly]
Terminated PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Apr 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kettering Health Network
For direct contact, visit the study record on ClinicalTrials.gov .